°æ±¸ bisphosphonate¸¦ º¹¿ëÇϴ ȯÀÚ¿¡¼ ¹ß»ýÇÑ bisphosphonate-related osteonecrosis of jaw¿¡ ´ëÇÑ ÀÓ»óÀû Ư¡ ¹× óġ: Áõ·Êº¸°í
Clinical feature and treatment of bisphosphonate-related osteonecrosis of jaw about oral bisphosphonate administrated patients: case reports
Ãֿ켺, À±ÇöÁß, ÀÌ»óÈ,
¼Ò¼Ó »ó¼¼Á¤º¸
Ãֿ켺 ( Choi Woo-Sung ) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿©Àǵµ¼º¸ðº´¿ø ±¸°¾Ç¾È¸é¿Ü°ú
À±ÇöÁß ( Yoon Hyun-Joong ) - °¡Å縯´ëÇб³ ¿©Àǵµ¼º¸ðº´¿ø ±¸°¾Ç¾È¸é¿Ü°ú
ÀÌ»óÈ ( Lee Sang-Hwa ) - °¡Å縯´ëÇб³ ¿©Àǵµ¼º¸ðº´¿ø ±¸°¾Ç¾È¸é¿Ü°ú
KMID : 0355620100360060508
Abstract
Bisphosphonates are used effectively for many medical conditions, such as multiple myeloma, Paget¡¯s disease, osteoporosis, etc. However, recently, osteonecrosis of the jaw was observed in patients receiving long-term bisphosphonate therapy, including oral administration. This osteonecrosis is refractory, and complete recovery is not guaranteed despite a standard treatment protocol being established by many associations related to oral and maxillofacial surgery. The treatment outcome of oral bisphosphonate-related osteonecrosis of jaw (BRONJ) is reported with a review of the relevant literature
Å°¿öµå
Bisphosphonate; Osteonecrosis; Osteoporosis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸